We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Genetic Discovery Could Circumvent Splenectomy for Cooley's Anemia Sufferers

By HospiMedica staff writers
Posted on 11 Jun 2008
New research may have discovered the precise role of a gene responsible for the mutated red blood cells (RBCs) in one of the world's most common blood disorders, beta-thalassemia (commonly known as Cooley's Anemia), which could prevent a splenectomy.

Researchers from the Weill Cornell Medical College (WCMC, New York, NY, USA) observed that in the thalassemic mice, a greater than normal percentage of erythroid cells were in S-phase, exhibiting an erythroblast-like morphology. More...
Thalassemic cells were associated with expression of cell cycle promoting genes such as EpoR, Jak2, Cyclin-A, Cdk2, Ki-67, and the anti-apoptotic protein Bcl-XL. They also differentiated less that normal erythroid ones in vitro. In order to investigate whether Janus kinase 2 (JAK2, a protein tyrosine kinase) could be responsible for the limited cell differentiation, the researchers administered a Jak2 inhibitor, numbered TG101209, to normal and thalassemic mice. The researchers found that exposure to TG101209 dramatically decreased the spleen size but also affected anemia. The study was published in the May14, 2008, online issue of the journal Blood.

"While our data do not exclude a role for apoptosis in erythropoiesis, we propose that expansion of the erythroid pool followed by limited cell differentiation exacerbates erythropoiesis in thalassemia,” concluded senior author Stefano Rivella, Ph.D., an assistant professor of genetic medicine in pediatrics at WCMC. "In addition, these results suggest that use of Jak2 inhibitors has the potential to profoundly change the management of this disorder.”

In Cooley's anemia, hemoglobin is mutated and non-functioning, resulting in a low RBC count. Common symptoms of the disease include fatigue, shortness of breath, and an enlarged spleen, called splenomegaly, caused by a buildup of malformed RBCs within the body. The spleen works to filter out these unhealthy cells in order to protect the body from harm, such as in a stroke, but eventually the spleen becomes over-stuffed and is commonly surgically removed (splenectomy) in order to prevent a potentially fatal burst. Unfortunately, after the spleen is removed, patients are at a much greater risk for stroke and infections. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent. The World Health Organization (WHO) has estimated that between 50,000-100,000 children are born with the disease every year.


Related Links:
Weill Cornell Medical College

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.